AU2019251289B2 - Combination of LIF inhibitors and PD-1 axis inhibitors for use in treating cancer - Google Patents

Combination of LIF inhibitors and PD-1 axis inhibitors for use in treating cancer Download PDF

Info

Publication number
AU2019251289B2
AU2019251289B2 AU2019251289A AU2019251289A AU2019251289B2 AU 2019251289 B2 AU2019251289 B2 AU 2019251289B2 AU 2019251289 A AU2019251289 A AU 2019251289A AU 2019251289 A AU2019251289 A AU 2019251289A AU 2019251289 B2 AU2019251289 B2 AU 2019251289B2
Authority
AU
Australia
Prior art keywords
amino acid
acid sequence
seq
set forth
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2019251289A
Other languages
English (en)
Other versions
AU2019251289A1 (en
AU2019251289A8 (en
Inventor
Judit Anido Folgueira
Ester BONFILL TEIXIDOR
Johan Fransson
Robin Matthew Hallett
Monica PASCUAL GARCIA
Ester PLANAS RIGOL
Joan Seoane Suarez
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institució Catalana de Recerca i Estudis Avançats
Fundació Privada Institut d'Investigació Oncològica Vall-Hebron
MedImmune Ltd
Original Assignee
Institució Catalana de Recerca i Estudis Avançats
Fundació Privada Institut d'Investigació Oncològica Vall-Hebron
MedImmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institució Catalana de Recerca i Estudis Avançats, Fundació Privada Institut d'Investigació Oncològica Vall-Hebron, MedImmune Ltd filed Critical Institució Catalana de Recerca i Estudis Avançats
Publication of AU2019251289A1 publication Critical patent/AU2019251289A1/en
Publication of AU2019251289A8 publication Critical patent/AU2019251289A8/en
Application granted granted Critical
Publication of AU2019251289B2 publication Critical patent/AU2019251289B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2019251289A 2018-04-12 2019-04-11 Combination of LIF inhibitors and PD-1 axis inhibitors for use in treating cancer Ceased AU2019251289B2 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
EP18382248 2018-04-12
EP18382248.5 2018-04-12
EP18382326.9 2018-05-14
EP18382326 2018-05-14
EP18382360 2018-05-25
EP18382360.8 2018-05-25
EP19382132 2019-02-22
EP19382132.9 2019-02-22
PCT/IB2019/000423 WO2019197903A1 (en) 2018-04-12 2019-04-11 Combination of lif inhibitors and pd-1 axis inhibitors for use in treating cancer

Publications (3)

Publication Number Publication Date
AU2019251289A1 AU2019251289A1 (en) 2020-11-26
AU2019251289A8 AU2019251289A8 (en) 2021-01-14
AU2019251289B2 true AU2019251289B2 (en) 2024-01-18

Family

ID=67060425

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019251289A Ceased AU2019251289B2 (en) 2018-04-12 2019-04-11 Combination of LIF inhibitors and PD-1 axis inhibitors for use in treating cancer

Country Status (11)

Country Link
US (1) US20210130453A1 (enExample)
EP (1) EP3774895A1 (enExample)
JP (2) JP7423598B2 (enExample)
KR (1) KR20210021287A (enExample)
CN (1) CN112585164A (enExample)
AU (1) AU2019251289B2 (enExample)
CA (1) CA3096779A1 (enExample)
IL (1) IL277918A (enExample)
MA (1) MA52231A (enExample)
SG (1) SG11202009966SA (enExample)
WO (1) WO2019197903A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4321219A3 (en) * 2016-12-19 2024-05-15 Medimmune Limited Antibodies against lif and uses thereof
EP3794031A2 (en) * 2018-05-14 2021-03-24 MedImmune Limited Antibodies against lif and dosage forms thereof
WO2021110873A1 (en) * 2019-12-04 2021-06-10 Medimmune Limited Antibodies against lif and uses thereof
JP7796032B2 (ja) * 2020-03-11 2026-01-08 パーデュー・リサーチ・ファウンデーション 免疫調節活性を持つ化合物およびその治療的使用
WO2023159152A2 (en) * 2022-02-17 2023-08-24 Immune-Onc Therapeutics, Inc. Combination therapy of lilrb antagonist and pd-1/pd-l1 axis inhibitor

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
AU4231393A (en) * 1992-05-08 1993-12-13 Genentech Inc. Antibodies to leukemia inhibitory factor
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
HUP0104865A3 (en) 1999-01-15 2004-07-28 Genentech Inc Polypeptide variants with altered effector function
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
EP2371860A1 (en) 2010-04-05 2011-10-05 Fundació Privada Institut d'Investigació Oncològica de Vall d'Hebron Antibody recognising human leukemia inhibitory factor (LIF) and use of anti-LIF antibodies in the treatment of diseases associated with unwanted cell proliferation
AU2015314980A1 (en) 2014-09-10 2017-03-02 The Regents Of The University Of California Targeting K-Ras-mediated signaling pathways and malignancy by anti-hLIF antibodies
EP3173483A1 (en) 2015-11-27 2017-05-31 Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron Agents for the treatment of diseases associated with undesired cell proliferation
US10583191B2 (en) * 2016-12-19 2020-03-10 Mosaic Biomedicals Slu Antibodies against LIF and uses thereof
EP4321219A3 (en) 2016-12-19 2024-05-15 Medimmune Limited Antibodies against lif and uses thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MAGRAM ET AL, 2017, XP002785420, Retrieved from the Internet <URL:http://northernbiologics.com/wp-content/uploads/2017/10/AACR-Molecular-targets-2017-poster.pdf> [retrieved on 20181008] *
SHINDO YOSHITARO ET AL, ANTICANCER RESEARCH JAN 2015, vol. 35, no. 1, January 2015 (2015-01-01), pages 129 - 136, XP002785419, ISSN: 1791-7530 *

Also Published As

Publication number Publication date
CN112585164A (zh) 2021-03-30
AU2019251289A1 (en) 2020-11-26
US20210130453A1 (en) 2021-05-06
JP2024054138A (ja) 2024-04-16
CA3096779A1 (en) 2019-10-17
JP7423598B2 (ja) 2024-01-29
MA52231A (fr) 2021-02-17
SG11202009966SA (en) 2020-11-27
AU2019251289A8 (en) 2021-01-14
WO2019197903A8 (en) 2020-02-20
JP2021521274A (ja) 2021-08-26
KR20210021287A (ko) 2021-02-25
WO2019197903A1 (en) 2019-10-17
EP3774895A1 (en) 2021-02-17
IL277918A (en) 2020-11-30

Similar Documents

Publication Publication Date Title
US10583191B2 (en) Antibodies against LIF and uses thereof
JP7423598B2 (ja) がんの治療で使用するためのｌｉｆ阻害剤とｐｄ－１軸阻害剤との組み合わせ
US20230042095A1 (en) Antibodies against lif and uses thereof
AU2019269131B2 (en) Antibodies against LIF and dosage forms thereof
AU2019291305B2 (en) Methods for improving response to anti-LIF antibody treatment in individuals with cancer
EA047583B1 (ru) Комбинация ингибиторов lif и ингибиторов оси pd-1 для применения в лечении рака
HK40049059A (en) Combination of lif inhibitors and pd-1 axis inhibitors for use in treating cancer
EA044934B1 (ru) Антитела к lif и лекарственные формы на их основе
EA049383B1 (ru) Способы улучшения ответа на лечение с помощью антитела к lif у индивидуумов, страдающих от рака
EA044914B1 (ru) Способы улучшения ответа на лечение с помощью антитела к lif у индивидуумов, страдающих от рака
CA3103369A1 (en) Combination of lif inhibitors and platinum-based antineoplastic agents for use in treating cancer
BR122024020696A2 (pt) Anticorpo recombinante que se liga ao fator inibidor de leucemia e composição farmacêutica compreendendo o referido anticorpo

Legal Events

Date Code Title Description
TH Corrigenda

Free format text: IN VOL 34 , NO 47 , PAGE(S) 6747 UNDER THE HEADING PCT APPLICATIONS THAT HAVE ENTERED THE NATIONAL PHASE - NAME INDEX UNDER THE NAME MEDIMMUNE LIMITED; FUNDACIO PRIVADA INSTITUF D'INVESTIGACIO ONCILOGICA DE VALL HEBRON; FUNDACIO PRIVADA INSTITUCIO CATALANA DE RECERCA I ESTUDIS AVANCATS, APPLICATION NO. 2019251289, UNDER INID (71) CORRECT THE CO-APPLICANT NAME TO FUNDACIO PRIVADA INSTITUT D'INVESTIGACIO ONCOLOGICA DE VALL HEBRON; UNDER INID (72) CORRECT THE CO-INVENTOR TO HALLETT, ROBIN MATTHEW

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired